Psoriatic arthritis: pharmacoeconomic considerations.
Tumor necrosis factor (TNF) antagonists provide a clinically and economically efficient treatment option for psoriatic arthritis (PsA). PsA is a chronic inflammatory disease affecting the musculoskeletal system that, if untreated, can be disabling due to the progressive joint damage and the considerable impact on functional status and health-related quality of life. Therapies for PsA have been disappointing until recently. Traditional disease-modifying drugs are used to control symptoms, but there is no evidence that they slow the progression of the damage in peripheral joints. The introduction of the TNF-alpha-blocking agents has revolutionized the therapeutic management of PsA. These drugs lessen symptoms and signs of inflammation, enhance quality of life and functional capacity, and hinder the evolution of structural joint damage. TNF-alpha blockers are very expensive and not easily available to all patients, either depending on a national system or private insurance. Nevertheless, recent pharmacoeconomic studies have demonstrated that TNF-alpha blockers are cost-effective treatment options for the musculoskeletal and cutaneous manifestations of psoriatic disease.
Olivieri
Ignazio
I
Rheumatology Department of Lucania, Ospedale San Carlo, Contrada Macchia Romana, Potenza, Italy. ignazioolivieri@tiscalinet.it
Mantovani
Lorenzo Giovanni
LG
D'Angelo
Salvatore
S
Padula
Angela
A
de Portu
Simona
S
D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000191:economics*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006801:Humans; D019057:Quality-Adjusted Life Years; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D014409:Tumor Necrosis Factor-alpha
Br J Dermatol. 2009 Jun;160(6):1264-72
19120346
Rheumatology (Oxford). 2006 Aug;45(8):1029-38
16782734
Curr Rheumatol Rep. 2006 Oct;8(5):355-63
16973109
Arthritis Rheum. 2005 Oct;52(10):3279-89
16200601
Nat Clin Pract Rheumatol. 2007 Dec;3(12):698-706
18037929
Ann Rheum Dis. 2006 Aug;65(8):1038-43
16439444
Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv65-9
16239392
J Rheumatol. 2008 Jan;35(1):137-41
18050372
Arthritis Rheum. 1991 Oct;34(10):1218-27
1930310
Pharmacoeconomics. 2008;26(2):121-9
18198932
J Am Acad Dermatol. 2006 Nov;55(5):829-35
17052489
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239
16948890
Ann Rheum Dis. 2006 Apr;65(4):423-32
16126792
Best Pract Res Clin Rheumatol. 2002 Dec;16(5):723-39
12473270
Expert Opin Pharmacother. 2009 Feb;10(2):271-82
19236198
Arthritis Rheum. 1997 Oct;40(10):1868-72
9336423
J Rheumatol. 2006 Feb;33(2):210-2
16465649
Br J Rheumatol. 1991 Aug;30(4):245-50
1863819
Rheumatology (Oxford). 2003 Jun;42(6):778-83
12730539
Ann Rheum Dis. 2006 Sep;65(9):1175-83
16540552
Rheumatology (Oxford). 2003 Jul;42(7):909-11
12826714
Arthritis Rheum. 2004 Jul;50(7):2264-72
15248226
Rheumatology (Oxford). 2006 Jul;45(7):790-1
16705044
J Rheumatol. 2008 Apr;35(4):668-73
18278834
Rheumatology (Oxford). 2003 Dec;42(12):1460-8
14523223
J Rheumatol. 2001 Aug;28(8):1842-6
11508587
Rheumatology (Oxford). 2008 Nov;47(11):1664-70
18725374
Lancet. 1997 May 17;349(9063):1436-42
9164317
Rheumatology (Oxford). 2007 Nov;46(11):1729-35
17956918
J Rheumatol. 1990 Jun;17(6):809-12
2388203
Br Med J (Clin Res Ed). 1982 Oct 2;285(6346):949-50
6811085
Rheumatology (Oxford). 2008 May;47(5):718-23
18400833
Arthritis Rheum. 1998 Jun;41(6):1103-10
9627021
J Drugs Dermatol. 2007 Mar;6(3):299-306
17373192
J Rheumatol. 1997 Mar;24(3):511-7
9058658
J Am Acad Dermatol. 1984 Nov;11(5 Pt 2):937-47
6389615
J Rheumatol. 2008 Jul;35(7):1434-7
18609740
Semin Arthritis Rheum. 2002 Feb;31(4):264-70
11836659
J Invest Dermatol. 1979 Nov;73(5 Pt 2):402-13
501139
J Am Acad Dermatol. 2002 Jun;46(6):850-60
12063481
J Rheumatol. 2006 Nov;33(11):2254-9
16960923
J Rheumatol. 2000 May;27(5):1241-6
10813294